The in vitro results revealed that GPAT-IN-125 (a glycerol-3-phosphate acyltransferase isoform inhibitor) and erastin (an SLC7A11 inhibitor) significantly decreased the viability of ovarian cancer cells and inhibited their proliferation. Here, GPAT3 is linked to ovarian carcinoma.